GSK allots as much as $2B for "bolt-on acquisitions" in India

10/3/2011 | Wall Street Journal, The

GlaxoSmithKline is looking to spend between $500 million and $2 billion on smaller, "bolt-on acquisitions" in India to secure its position in emerging markets, CEO Andrew Witty said. He said GSK is not willing to overpay. "We already have an enviable brand in India so there is no need for us to pay a strategic premium," Witty said. "Others might need to do that, but we don't."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA